Deals with biotech companies are becoming more important as pharmaceutical companies go through restructuring, writes John Carroll at FierceBiotech. "We've been seeing a lot more smart biotechs doing licensing deals at an early stage this year. Preclinical pacts are not at all uncommon," he says. However, Carroll notes that deal terminations by pharma companies are occurring at earlier stages. "So not only do biotechs have to get smarter about collaborations, they also need to build in an exit door so they can take all their IP with them if a partnership turns sour," he adds.
Dec 24, 2011